Case-Matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 4, 2006, Pages 1092-1099

  Fletcher, Sophie G ^a   Mills, Stacey E ^a   Smolkin, Mark E ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Brachytherapy; Locally advanced prostate cancer; Prostate cancer; Radiation therapy; Radical prostatectomy

Indexed keywords

ANTIGENS; DATA REDUCTION; DISEASE CONTROL; PATIENT TREATMENT; RADIOTHERAPY; SURGERY;

BRACHYTHERAPY; LOCALLY ADVANCED PROSTATE CANCER; PROSTATE CANCER; RADICAL PROSTATECTOMY;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER LOCALIZATION; CANCER RELAPSE; CANCER RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33750338077     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.06.019     Document Type: Article

References (40)

1. Noldus J., Graefen M., Haese A., et al. Stage migration in clinically localized prostate cancer. Eur Urol 38 (2000) 74-78
2. Meng M.V., Elkin E.P., Latini D.M., et al. Treatment of patients with high risk localized prostate cancer: Results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 173 (2005) 1557-1561
3. Catalona W.J., and Smith D.S. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 160 (1998) 2428-2434
4. Walsh P.C. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: A structured debate. J Urol 163 (2000) 1802-1807
5. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
6. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
7. Ragde H., Korb L.J., Elgamal A.A., et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 89 (2000) 135-141
8. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
9. Cheng W.S., Frydenberg M., Bergstralh E.J., et al. Radical prostatectomy for pathologic stage C prostate cancer: Influence of pathologic variables and adjuvant treatment on disease outcome. Urology 42 (1993) 283-291
10. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
11. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17 (1999) 517-522
12. Stone N.N., and Stock R.G. Prostate brachytherapy: Treatment strategies. J Urol 162 (1999) 421-426
13. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2002) 4567-4573
14. Soloway M.S., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167 (2002) 112-116
15. Klotz L.H., Goldenberg S.L., Jewett M.A., et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170 (2003) 791-794
16. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37 (1997) 247-252
17. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
18. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
19. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
20. Coblentz T.R., Bissonette E.A., Williams K.R., et al. Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: Early results in high risk patients. Prostate Cancer Prostatic Dis 5 (2002) 219-225
21. Copp H., Bissonette E.A., and Theodorescu D. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer. Urology 65 (2005) 1146-1151
22. Barry M.J., Albertsen P.C., Bagshaw M.A., et al. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: A retrospective analysis. Cancer 91 (2001) 2302-2314
23. Akakura K., Isaka S., Akimoto S., et al. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: Radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 54 (1999) 313-318
24. Dattoli M., Wallner K., Sorace R., et al. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 35 (1996) 875-879
25. Sylvester J.E., Blasko J.C., Grimm P.D., et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience. Int J Radiat Oncol Biol Phys 57 (2003) 944-952
26. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42-S46 discussion S46-S47
27. Sobin L.H., and Fleming I.D. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80 (1997) 1803-1804
28. Critz F.A., Williams W.H., Holladay C.T., et al. Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 54 (1999) 968-971
29. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
30. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
31. Meyer F., Bairati I., Bedard C., et al. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer. Urology 58 (2001) 71-77
32. Nejat R.J., Rashid H.H., Bagiella E., et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 164 (2000) 1891-1894
33. Miller N., Smolkin M.E., Bissonette E., et al. Undetectable prostate specific antigen at 6-12 months. Cancer 103 (2005) 2499-2506
34. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
35. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 (1997) 1441-1445
36. Roberts S.G., Blute M.L., Bergstralh E.J., et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76 (2001) 576-581
37. Okotie O.T., Aronson W.J., Wieder J.A., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171 (2004) 2260-2264
38. Sartor C.I., Strawderman M.H., Lin X.H., et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38 (1997) 941-947
39. D'Amico A.V., Moul J., Carroll P.R., et al. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 173 (2005) 1572-1576
40. Sandler H.M., Dunn R.L., McLaughlin P.W., et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48 (2000) 629-633